- Collaboration combines Sosei Heptares' leading structure-based drug design platform with PharmEnable's advanced artificial intelligence-enabled and medicinal chemistry technologies
- Joint drug discovery programme on a challenging GPCR target with key role in neurological diseases
PR Newswire
TOKYO and CAMBRIDGE, England, Jan. 12, 2021